DIMEPRANOL ACEDOBEN

Details

Stereochemistry	RACEMIC
Molecular Formula	C9H9NO3.C5H13NO
Molecular Weight	282.3355
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O

InChI

InChIKey=FJFQBKRMSCKTSE-UHFFFAOYSA-N

InChI=1S/C9H9NO3.C5H13NO/c1-6(11)10-8-4-2-7(3-5-8)9(12)13;1-5(7)4-6(2)3/h2-5H,1H3,(H,10,11)(H,12,13);5,7H,4H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C9H9NO3
Molecular Weight	179.1727
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C5H13NO
Molecular Weight	103.1628
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.medicines.org.uk/emc/medicine/27089
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2431857

Acedoben (4-acetamidobenzoic acid) is a benzoic acid derivative and a metabolite of benzocaine. It is a component of immunomodulatory drug inosine pranobex, which is used to treat mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
immune response 6 Target ID: GO:0006955 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2431857	Modulator 828

Conditions

Condition	Modality	Highest Phase	Product
Herpes simplex infection 28 Sources: https://www.medicines.org.uk/emc/medicine/27089	Primary	Approved 8429	IMUNOVIR Approved Use Imunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date 1983
Genital warts 14 Sources: https://www.medicines.org.uk/emc/medicine/27089	Primary	Approved 8429	IMUNOVIR Approved Use Imunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date 1983
Subacute sclerosing panencephalitis 4 Sources: https://www.medicines.org.uk/emc/medicine/27089	Primary	Approved 8429	IMUNOVIR Approved Use Imunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date 1983

PubMed

Title	Date	PubMed
Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.	1986 Nov	2431857
Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection.	1993 Jun	7687120
Ellagic acid inhibited 2-aminofluorene and p-aminobenzoic acid acetylation by mononuclear leucocytes from Sprague-Dawley rats.	2001	11258539
Effects of the butylated hydroxyanisole and butylated hydroxytoluene on the DNA adduct formation and arylamines N-acetyltransferase activity in human colon tumor cells.	2001 Mar-Apr	11396144
Contribution of hydrogen bonding to protein stability estimated from isotope effects.	2002 Feb 19	11841202
Separate coding of different gaze directions in the superior temporal sulcus and inferior parietal lobule.	2007 Jan 9	17208181
The human brain in numbers: a linearly scaled-up primate brain.	2009	19915731
Regioselective carboxylation of catechol by 3,4-dihydroxybenzoate decarboxylase of Enterobacter cloacae P.	2010 May	20131080

Patents

Sample Use Guides

In Vivo Use Guide

Mucocutaneous herpes simplex: 1 g q.d.s. (4g daily), for 7 -14 days. Genital warts: 1g t.d.s. (3g daily), for 14-28 days as adjunctive therapy to podophyllin or carbon dioxide laser. Subacute sclerosing panencephalitis (SSPE): 50-100mg/kg daily, in divided does every 4 hours.

Route of Administration: Oral

In Vitro Use Guide

Inosine pranobex has been shown to stimulate various indices of metabolic activity of macrophages and monocytes. In vitro exposure to inosine pranobex or to 24-hour supernatants obtained from mononuclear cells pretreated with the drug restored chemotaxis to normal or near normal levels. Incubation with inosine pranobex in vitro stimulated the production of interleukin-l (lymphocyte activating factor) in human monocytes.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:05:56 GMT 2023` Edited by `admin` on `Fri Dec 15 16:05:56 GMT 2023`
Record UNII	1V339IMQ38
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DIMEPRANOL ACEDOBEN

Official Name

English

DIMEPRANOL ACEDOBEN [USAN]

Common Name

English

DIMEPRANOL-4-ACETAMIDOBENZOATE

Common Name

English

(±)-1-(DIMETHYLAMINO)-2-PROPANOL, P-ACETAMIDOBENZOATE (SALT)

Common Name

English

2-PROPANOL, 1-(DIMETHYLAMINO)-, (±)-, 4-(ACETYLAMINO)BENZOATE (SALT)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C308